from the go-fullerenes dept.
From PR Newswire on Yahoo comes this news from Toronto: "William Multi-Tech Inc., (“Multi-Tech'') (TSE:WIM – news) announced today that C Sixty Inc. (“C Sixty'') a privately held biotechnology company, in which Multi-Tech has a 40% ownership interest, has begun upscale manufacturing of its lead fullerene based drug candidate for treatment of patients with AIDS and AIDS related disease. As a novel anti-HIV drug, C Sixty's product has to date demonstrated potent activity against multiple strains of the HIV virus including drug resistant and de-novo resistant strains of the virus…The potential for widespread applications of C Sixty's technology in medicine, positions the company as a leader in the emerging field of Nanotechnology and its related Biotechnology market. "
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.